NO20025784D0 - Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme - Google Patents
Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter sammeInfo
- Publication number
- NO20025784D0 NO20025784D0 NO20025784A NO20025784A NO20025784D0 NO 20025784 D0 NO20025784 D0 NO 20025784D0 NO 20025784 A NO20025784 A NO 20025784A NO 20025784 A NO20025784 A NO 20025784A NO 20025784 D0 NO20025784 D0 NO 20025784D0
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical formulation
- substance
- hmg
- chemical synthesis
- coa reductase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2000/000773 WO2001093860A1 (en) | 2000-06-09 | 2000-06-09 | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US09/591,322 US6531507B1 (en) | 2000-06-09 | 2000-06-09 | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20025784D0 true NO20025784D0 (no) | 2002-12-02 |
NO20025784L NO20025784L (no) | 2002-12-02 |
Family
ID=26318615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20025784A NO20025784L (no) | 2000-06-09 | 2002-12-02 | Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme |
Country Status (19)
Country | Link |
---|---|
US (1) | US6531507B1 (no) |
EP (1) | EP1292293B1 (no) |
JP (1) | JP2004501121A (no) |
AT (1) | ATE260101T1 (no) |
AU (2) | AU2000249434B2 (no) |
BG (1) | BG107360A (no) |
CA (1) | CA2412326A1 (no) |
CZ (1) | CZ20023826A3 (no) |
DE (1) | DE60008608T2 (no) |
ES (1) | ES2215050T3 (no) |
HR (1) | HRP20020950A2 (no) |
HU (1) | HUP0301325A3 (no) |
NO (1) | NO20025784L (no) |
PL (1) | PL362764A1 (no) |
RU (1) | RU2246943C2 (no) |
SI (1) | SI1292293T1 (no) |
SK (1) | SK16982002A3 (no) |
UA (1) | UA70410C2 (no) |
WO (1) | WO2001093860A1 (no) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110196039A9 (en) * | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
US6806290B2 (en) * | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
AU2002219175A1 (en) * | 2000-12-21 | 2002-07-01 | Ciba Speciality Chemicals Holding Inc. | Crystalline forms of cerivastatin sodium |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
WO2003000239A1 (en) * | 2001-06-21 | 2003-01-03 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions containing pravastatin |
US20040180087A1 (en) * | 2001-06-21 | 2004-09-16 | Boyong Li | Stable controlled release pharmaceutical compositions containing pravastatin |
WO2003013607A1 (en) * | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR |
AU2002353659A1 (en) * | 2001-12-18 | 2003-07-15 | Synthon B.V. | Simvastatin dosage forms |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
US20060035941A1 (en) * | 2002-06-13 | 2006-02-16 | Guang-Pei Chen | Calcium salts of indole derived statins |
US20060029668A1 (en) * | 2002-10-24 | 2006-02-09 | Ron Eyal S | Sustained release L-arginine formulations and methods of manufacture and use |
KR20050083827A (ko) * | 2002-10-24 | 2005-08-26 | 이노스 파마슈티칼스, 인코포레이티드 | 서방성 l-아르기닌 포뮬레이션 및 이의 제조방법 및 용도 |
US20080145424A1 (en) * | 2002-10-24 | 2008-06-19 | Enos Phramaceuticals, Inc. | Sustained release L-arginine formulations and methods of manufacture and use |
DE60319877T2 (de) * | 2002-12-20 | 2009-04-30 | Pfizer Products Inc., Groton | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
EP1675619A4 (en) * | 2003-09-29 | 2010-10-06 | Palmetto Pharmaceuticals Llc | EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES |
US8163797B2 (en) * | 2003-12-31 | 2012-04-24 | Actavis Elizabeth Llc | Method of treating with stable pravastatin formulation |
US20080242725A1 (en) * | 2004-03-01 | 2008-10-02 | Janez Kerc | Pharmaceutical Composition |
PT1727795E (pt) | 2004-03-17 | 2012-04-11 | Ranbaxy Lab Ltd | Processo para a produção de atorvastatina cálcica na forma amorfa |
US7491263B2 (en) * | 2004-04-05 | 2009-02-17 | Technology Innovation, Llc | Storage assembly |
CA2573316A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
NZ552389A (en) * | 2004-08-06 | 2009-05-31 | Transform Pharmaceuticals Inc | Statin pharmaceutical compositions and related methods of treatment |
US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
US20090208539A1 (en) | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
CA2595651A1 (en) * | 2005-01-24 | 2006-08-03 | Enos Pharmaceuticals, Inc. | Methods of treating various conditions by administration of sustained release l-arginine |
WO2006123358A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Stabilized atorvastatin-containing formulation |
US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
JP4813841B2 (ja) * | 2005-07-25 | 2011-11-09 | キユーピー株式会社 | プラバスタチンナトリウムの製造方法 |
CA2615941A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
US7772273B2 (en) * | 2006-02-10 | 2010-08-10 | Lifecycle Pharma A/S | Stabilized atorvastatin |
BRPI0708191A2 (pt) * | 2006-02-24 | 2012-05-29 | Teva Pharma | " composições farmacêuticas de fluvastatina sódica " |
DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
RU2014124118A (ru) | 2011-11-15 | 2015-12-27 | Др. Редди'С Лабораторис Лтд. | Фармацевтические препараты, включающие аторвастатин и глимепирид |
KR101466617B1 (ko) * | 2011-11-17 | 2014-11-28 | 한미약품 주식회사 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8105781A1 (es) * | 1979-07-27 | 1981-06-16 | Sankyo Co | Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos. |
US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
TW474809B (en) | 1995-07-03 | 2002-02-01 | Sankyo Co | A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers |
SI1148049T1 (en) | 1995-07-17 | 2005-02-28 | Warner-Lambert Company | Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
ES2183023T3 (es) | 1995-12-22 | 2003-03-16 | Kowa Co | Composicion farmaceutica estabilizada con un agente basico. |
SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
-
2000
- 2000-06-09 WO PCT/IB2000/000773 patent/WO2001093860A1/en active IP Right Grant
- 2000-06-09 PL PL00362764A patent/PL362764A1/xx not_active Application Discontinuation
- 2000-06-09 SI SI200030324T patent/SI1292293T1/xx unknown
- 2000-06-09 AT AT00931486T patent/ATE260101T1/de active
- 2000-06-09 CA CA002412326A patent/CA2412326A1/en not_active Abandoned
- 2000-06-09 AU AU2000249434A patent/AU2000249434B2/en not_active Ceased
- 2000-06-09 AU AU4943400A patent/AU4943400A/xx active Pending
- 2000-06-09 US US09/591,322 patent/US6531507B1/en not_active Expired - Fee Related
- 2000-06-09 HU HU0301325A patent/HUP0301325A3/hu unknown
- 2000-06-09 SK SK1698-2002A patent/SK16982002A3/sk not_active Application Discontinuation
- 2000-06-09 EP EP00931486A patent/EP1292293B1/en not_active Revoked
- 2000-06-09 CZ CZ20023826A patent/CZ20023826A3/cs unknown
- 2000-06-09 ES ES00931486T patent/ES2215050T3/es not_active Expired - Lifetime
- 2000-06-09 DE DE60008608T patent/DE60008608T2/de not_active Expired - Lifetime
- 2000-06-09 RU RU2002134764/15A patent/RU2246943C2/ru not_active IP Right Cessation
- 2000-06-09 JP JP2002501433A patent/JP2004501121A/ja active Pending
- 2000-09-06 UA UA2002119464A patent/UA70410C2/uk unknown
-
2002
- 2002-12-02 HR HRP20020950 patent/HRP20020950A2/hr not_active Application Discontinuation
- 2002-12-02 NO NO20025784A patent/NO20025784L/no not_active Application Discontinuation
- 2002-12-06 BG BG107360A patent/BG107360A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20020950A2 (en) | 2004-12-31 |
AU4943400A (en) | 2001-12-17 |
EP1292293B1 (en) | 2004-02-25 |
PL362764A1 (en) | 2004-11-02 |
DE60008608T2 (de) | 2004-12-30 |
WO2001093860A1 (en) | 2001-12-13 |
SI1292293T1 (en) | 2004-06-30 |
RU2246943C2 (ru) | 2005-02-27 |
SK16982002A3 (sk) | 2003-04-01 |
US6531507B1 (en) | 2003-03-11 |
JP2004501121A (ja) | 2004-01-15 |
BG107360A (bg) | 2003-11-28 |
UA70410C2 (en) | 2004-10-15 |
HUP0301325A3 (en) | 2004-03-01 |
NO20025784L (no) | 2002-12-02 |
EP1292293A1 (en) | 2003-03-19 |
CA2412326A1 (en) | 2001-12-13 |
ES2215050T3 (es) | 2004-10-01 |
AU2000249434B2 (en) | 2006-02-02 |
CZ20023826A3 (cs) | 2003-04-16 |
HUP0301325A2 (hu) | 2003-11-28 |
ATE260101T1 (de) | 2004-03-15 |
DE60008608D1 (de) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20025784L (no) | Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme | |
NZ511260A (en) | Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor | |
IL187261A0 (en) | Crystals of the sodium salt of pravastatin | |
IS5891A (is) | Ný sölt HMG-CoA redúktasatálma | |
ATE284396T1 (de) | Verfahren zur bereitstellung von hochreinen hmg- coa reductase hemmer | |
WO2000048626A3 (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease | |
IL141785A0 (en) | A pharmaceutical composition containing an ap2 inhibitor | |
DE69909508D1 (de) | Verfahren zur herstellung von simvastatin und deren analogen | |
ATE418979T2 (de) | Stabilisiertes arzneimittel und arzneizubereitung | |
YU88602A (sh) | Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže | |
NZ535910A (en) | Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying | |
CO5611117A2 (es) | Combinacion de compuestos organicos | |
TH52206A (th) | สารที่รวมเข้าด้วยกันของ สแททิน-คาร์บอกซิแอลคิลอีเธอร์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |